Glycated apolipoprotein B and myocardial infarction

被引:27
作者
Misciagna, G.
Logroscino, G.
De Michele, G.
Guerra, V.
Cisternino, A. M.
Caruso, M. G.
Trevisan, M. [1 ]
机构
[1] SUNY Buffalo, Off Dean, Sch Publ Hlth & Hlth Profess, Buffalo, NY 14260 USA
[2] IRCCS, S De Bellis Osped, Lab Epidemiol, I-70013 Castellana Bari, Italy
[3] Harvard Univ, Dept Epidemiol, Harvard Sch Publ Hlth, Boston, MA 02115 USA
[4] IRCCS S De Bellis, Biochim Lab, Castellana Bari, Italy
关键词
apolipoprotein B; glycation; myocardial infarction; cohort study;
D O I
10.1016/j.numecd.2006.09.005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims: To evaluate the association of serum concentrations of glycated apolipoprotein B (ApoBg) with the incidence of myocardial infarction (MI) in subjects with and without diabetes. Methods: The design is a nested case-control study. The cohort included 5632 subjects over 50 years of age attending the clinical Laboratories of a small geographic area in southern Italy. After five years, 4563 subjects were traced and 103 had developed MI. We sampled from the cohort two controls for each incident case of MI, frequency matched for sex and diabetes. ApoBg was measured using a monoclonal antibody. Logistic regression was used for statistical analysis of the data. Results: ApoBg at baseline was higher in subjects who developed myocardial infarction than in controls in both non-diabetic and diabetic subjects (t test, P = 0.009 and P = 0.05 respectively). MI odds ratio in the third tertile of ApoBg was 2.01 (95% CI 0.93-4.33) in non-diabetic and 2.88 (0.85-9.68) in diabetic subjects (chi-square test for trend; non-diabetics P = 0.03, diabetics P = 0.06). Serum triglycerides, cholesterol, HDL and LDL cholesterol, glucose and insulin were not associated with MI (P > 0.10). Conclusion: ApoBg at baseline is directly associated with the development of MI in the following five years in both diabetic and non-diabetic individuals. (C) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:6 / 12
页数:7
相关论文
共 24 条
[1]   Determinants of glycated LDL levels in nondiabetic and diabetic hyperlipidaemic patients in Kuwait [J].
Akanji, AO ;
Abdella, N ;
Mojiminiyi, OA .
CLINICA CHIMICA ACTA, 2002, 317 (1-2) :171-176
[2]  
[Anonymous], 1992, VASC DIS, DOI DOI 10.1007/978-1-4614-7524-8_11
[3]  
Aronson D, 2001, CONTEMP CARDIOL, P247
[4]   GLYCOSYLATED LOW-DENSITY-LIPOPROTEIN IS MORE SENSITIVE TO OXIDATION - IMPLICATIONS FOR THE DIABETIC PATIENT [J].
BOWIE, A ;
OWENS, D ;
COLLINS, P ;
JOHNSON, A ;
TOMKIN, GH .
ATHEROSCLEROSIS, 1993, 102 (01) :63-67
[5]  
COHEN MP, 1993, EUR J CLIN CHEM CLIN, V31, P707
[6]   Glycated low density lipoproteins modify platelet properties: A compositional and functional study [J].
Ferretti, G ;
Rabini, RA ;
Bacchetti, T ;
Vignini, A ;
Salvolini, E ;
Ravaglia, F ;
Curatola, G ;
Mazzanti, L .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (05) :2180-2184
[7]   Advanced glycation end products in nondiabetic patients with coronary artery disease [J].
Kanauchi, M ;
Tsujimoto, N ;
Hashimoto, T .
DIABETES CARE, 2001, 24 (09) :1620-1623
[8]   Increased serum concentrations of advanced glycation end products: a marker of coronary artery disease activity in type 2 diabetic patients [J].
Kiuchi, K ;
Nejima, J ;
Takano, T ;
Ohta, M ;
Hashimoto, H .
HEART, 2001, 85 (01) :87-91
[9]  
KORTLANDT W, 1993, DIABETES NUTR METAB, V6, P231
[10]   Lipids and lipoproteins in patients with type 2 diabetes [J].
Krauss, RM .
DIABETES CARE, 2004, 27 (06) :1496-1504